NanoViricides Inc. Common Stock (NNVC)
Stock · AMEX · Health Care
$1.37as of 10/16/2026
Price chart
Active signals
NNVC Signal Track Record
How signals performed across all stocks →What NNVC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -0.3% | 50% | September 21, 2026 |
| Bollinger Band Breakout | 28 | -7.2% | 29% | September 21, 2026 |
| Bollinger Band Breakdown | 19 | +5.0% | 63% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +2.1% | 53% | October 1, 2026 |
| Any 20-session window (baseline) | -1.8% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the tre…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.nanoviricides.com/
Fundamentals
- 1-day range
- $1.3$1.4
- Market cap
- $35.56M
- P/E (trailing)
- —
- P/E (forward)
- -3.91
- EPS (trailing)
- $-0.41
- Dividend yield
- —
- Beta
- 1.91
- Avg. volume
- 418.5K
- Dividend pay date
- September 24, 2019
Forecasts
2 analyst ratings
NanoViricides Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- SERSerina Therapeutics Inc. Common Stock$1.72▼ 3.91%Market cap $35.24MP/E —$1.22$5.29
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| SER Serina Therapeutics Inc. Common Stock | $35.24M | — | $1.72 | ▼ 3.91% | $1.22$5.29 |
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Wellbenzinga · 10/13/2026
- NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026Yahoo · 10/6/2026
- NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 LivesYahoo · 10/5/2026
- NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early EnrollmentBenzinga · 10/5/2026
- NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical TrialsYahoo · 9/29/2026
- Nanoviricides Q4 EPS $(0.10), InlineBenzinga · 9/28/2026
- Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricidesYahoo · 9/28/2026
- Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricidesYahoo · 9/23/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 9/21/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.84M
- Total value held
- $1.67M
- Institutional holders
- 46
- Unknown511.5K
- Unknown225.4K
- Unknown213.4K
- Unknown158.8K
- Unknown134.9K
- Unknown105.0K
- Unknown99.0K
- Unknown58.1K
- Unknown54.2K
- Unknown36.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
NNVC Announces Phase II Trials for NV-387 in Ebola and Monkeypox
NanoViricides filed its annual report and confirmed that its broad‑spectrum antiviral candidate NV‑387 is now in Phase II clinical trials. The company reported fourth‑quarter earnings per share of $0.10, which matched analysts’ expectations. Enrollment and dosing have begun for an Ebola study, and a separate Phase II trial for monkeypox started in the Democratic Republic of Congo, keeping the drug’s development momentum active while the stock trades near its $1.50 support level.
NNVC Announces Phase II Trials for NV-387 in Ebola and Monkeypox. NanoViricides filed its annual report and confirmed that its broad‑spectrum antiviral candidate NV‑387 is now in Phase II clinical trials. The company reported fourth‑quarter earnings per share of $0.10, which matched analysts’ expectations. Enrollment and dosing have begun for an Ebola study, and a separate Phase II trial for monkeypox started in the Democratic Republic of Congo, keeping the drug’s development momentum active while the stock trades near its $1.50 support level.